CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with poor outcomes with current therapies. Gemcitabine is the primary adjuvant drug used clinically, but its effectiveness is limited. In this study, our objective was to utilize a rationale-driven approach to identify novel biomarkers...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Colbert, Lauren E., Petrova, Aleksandra V., Fisher, Sarah B., Pantazides, Brooke G., Madden, Matthew Z., Hardy, Claire W., Warren, Matthew D., Pan, Yunfeng, Nagaraju, Ganji P., Liu, Elaine A., Saka, Burcu, Hall, William A., Shelton, Joseph W., Gandhi, Khanjan, Pauly, Rini, Kowalski, Jeanne, Kooby, David A., El-Rayes, Bassel F., Staley, Charles A., Adsay, N. Volkan, Curran, Walter J., Landry, Jerome C., Maithel, Shishir K., Yu, David S.
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4025946/
https://ncbi.nlm.nih.gov/pubmed/24626090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-13-1996
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы